Stryker (NYSE:SYK) Announces Quarterly Earnings Results

Stryker (NYSE:SYK) issued its earnings results on Thursday. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38), FiscalAI reports. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.36 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.84 EPS. Stryker updated its FY 2026 guidance to 14.900-15.100 EPS.

Here are the key takeaways from Stryker’s conference call:

• The company experienced a late?Q1 cyber incident that caused a global operational disruption, delayed shipments and revenue recognition, and reduced manufacturing absorption; Stryker says systems were restored and manufacturing was fully operational by the week of April 1, with results expected to normalize over the year.
• Stryker reiterated full?year guidance despite the disruption, forecasting organic net sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10, expecting most lost Q1 sales to be recovered throughout the rest of 2026.
• Q1 headline metrics were muted—organic sales growth of 2.4% (U.S. 1.9%, international 3.9%), adjusted EPS of $2.60 (down 8.5% vs. 2025), adjusted gross margin 63.6% (?190 bps) and adjusted operating margin 21.1% (?180 bps), with tariffs, higher interest expense and the cyber event cited as drivers.
• M&A remains active—Stryker announced the agreement to acquire Amplitude Vascular Systems (expected to close in Q2) to expand peripheral vascular and broader cardiovascular offerings and said it has capacity to pursue additional acquisitions (gross debt/EBITDA ~2.1x).
• Organizational and product momentum in orthopedics—Stryker launched the consolidated Ortho Tech segment (Mako + Enabling Tech + instruments), reported a record Q1 for Mako installations, plans a Mako Shoulder full launch on Mako 4 midyear, and cited strong early feedback for new robotic and instrument products.

Stryker Trading Down 0.2%

SYK stock traded down $0.49 during trading on Thursday, hitting $314.64. The company had a trading volume of 2,751,278 shares, compared to its average volume of 1,773,260. The business has a 50-day moving average of $345.67 and a 200-day moving average of $356.95. Stryker has a one year low of $311.31 and a one year high of $404.87. The stock has a market cap of $120.50 billion, a PE ratio of 37.46, a PEG ratio of 1.84 and a beta of 0.92. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is presently 41.90%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SYK shares. Leerink Partners started coverage on Stryker in a report on Monday, April 13th. They set an “outperform” rating and a $410.00 price target on the stock. Truist Financial reduced their price target on Stryker from $395.00 to $380.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Needham & Company LLC boosted their price target on Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Robert W. Baird set a $437.00 price target on Stryker in a report on Friday, January 30th. Finally, Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $421.11.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Strong cash flow and profitability expansion — Reported net income, operating profit and cash from operations rose materially year-over-year (cash from ops jumped sharply), supporting balance-sheet strength and capital spending. Quiver Quantitative: Q1 results
• Positive Sentiment: Company maintained FY?2026 EPS guidance (14.900–15.100), signaling management confidence in full?year recovery despite the soft quarter. Reuters: misses estimates, maintains outlook
• Neutral Sentiment: Company highlighted quick operational recovery from a recent cyber incident; management framed the issue as contained and service delivery resumed. WSJ: cyberattack recovery
• Neutral Sentiment: Ongoing commercial wins and government contract awards provide recurring revenue tailwinds, but these are modest relative to total sales. Quiver: gov’t contracts & institutional activity
• Negative Sentiment: Earnings and revenue missed consensus — Q1 adjusted EPS missed estimates and revenue growth was only ~2.6%, below Street expectations, driving the initial negative market reaction. Zacks: EPS & revenue lag
• Negative Sentiment: Demand weakness in implants and complex-procedure devices weighed on results and led to a contraction in adjusted operating margin (down ~180 bps) and lower adjusted EPS versus prior year. GlobeNewswire: operating results & margin details
• Negative Sentiment: Insider and large institutional selling noted in filings and data feeds, which can add downward pressure on the stock in the near term. Quiver: insider & hedge fund activity

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.60% of the stock is owned by insiders.

Institutional Trading of Stryker

Several institutional investors have recently added to or reduced their stakes in SYK. Brighton Jones LLC boosted its holdings in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new position in shares of Stryker during the 2nd quarter worth approximately $205,000. Marshall Wace LLP boosted its holdings in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares in the last quarter. Nebula Research & Development LLC bought a new position in shares of Stryker during the 2nd quarter worth approximately $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker during the 2nd quarter worth approximately $253,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.